Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
AKTIENPREIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionNixon Peabody Trust Co
Latest Disclosed Ownership2,322 shares
Latest Disclosed Value $ 768,280
Nixon Peabody Trust Co reports 0.64% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On April 27, 2026 - Nixon Peabody Trust Co filed a 13F-HR form disclosing ownership of 2,322 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $663,395 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 2,337 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -0.64% during the quarter. The current value of the position is $584,680 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-27 2026-03-31 13F Alnylam Pharmaceuticals Com 02043Q107 2,322 -15 -0.64 768 -17.33 0.0611
2026-02-06 2025-12-31 13F Alnylam Pharmaceuticals Com 02043Q107 2,337 -10 -0.43 929 -13.18 0.0704
2025-10-17 2025-09-30 13F Alnylam Pharmaceuticals Com 02043Q107 2,347 10 0.43 1,070 40.42 0.0784
2025-08-08 2025-06-30 13F Alnylam Pharmaceuticals Com 02043Q107 2,337 60 2.64 762 24.10 0.0590
2025-04-10 2025-03-31 13F Alnylam Pharmaceuticals Com 02043Q107 2,277 -16 -0.70 615 13.91 0.0522
2025-02-05 2024-12-31 13F Alnylam Pharmaceuticals Com 02043Q107 2,293 43 1.91 540 -12.78 0.0445
2024-11-07 2024-09-30 13F Alnylam Pharmaceuticals Com 02043Q107 2,250 -1,050 -31.82 619 -22.85 0.0515
2024-07-26 2024-06-30 13F Alnylam Pharmaceuticals Com 02043Q107 3,300 0 0.00 802 62.47 0.0713
2024-05-07 2024-03-31 13F Alnylam Pharmaceuticals Com 02043Q107 3,300 0 0.00 493 -21.87 0.0453
2024-02-09 2023-12-31 13F Alnylam Pharmaceuticals Com 02043Q107 3,300 1,800 120.00 632 138.11 0.0708
2023-10-23 2023-09-30 13F Alnylam Pharmaceuticals Com 02043Q107 1,500 0 0.00 266 -6.69 0.2224
2023-07-27 2023-06-30 13F Alnylam Pharmaceuticals Com 02043Q107 1,500 0 0.00 285 -5.33 0.2311
2023-05-12 2023-03-31 13F Alnylam Pharmaceuticals Com 02043Q107 1,500 0 0.00 300 -15.73 0.2102
2023-02-09 2022-12-31 13F Alnylam Pharmaceuticals Com 02043Q107 1,500 0 0.00 356 18.67 0.2892
2023-03-15 2022-09-30 13F/A-1 Alnylam Pharmaceuticals Com 02043Q107 1,500 0 0.00 300 36.99 0.2546
2022-11-10 2022-09-30 13F Alnylam Pharmaceuticals Com 02043Q107 1,500 0 300 0.1354
2022-08-11 2022-06-30 13F Alnylam Pharmaceuticals Com 02043Q107 1,500 0 0.00 219 -10.61 0.0990
2022-05-13 2022-03-31 13F Alnylam Pharmaceuticals Com 02043Q107 1,500 0 0.00 245 -3.54 0.0843
2022-02-08 2021-12-31 13F Alnylam Pharmaceuticals Com 02043Q107 1,500 0 0.00 254 -10.25 0.0769
2021-11-04 2021-09-30 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 1,500 -500 -25.00 283 -16.52 0.1023
2021-07-30 2021-06-30 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 2,000 0 0.00 339 20.21 0.1306
2021-04-26 2021-03-31 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 2,000 0 0.00 282 8.46 0.1143
2021-02-10 2020-12-31 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 2,000 0 0.00 260 -10.65 0.1097
2020-11-03 2020-09-30 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 2,000 0 0.00 291 -1.69 0.1340
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 2,000 0 0.00 296 35.78 0.1502
2020-04-23 2020-03-31 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 2,000 0 0.00 218 -5.22 0.1347
2020-01-24 2019-12-31 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 2,000 2,000 230 0.1146
2018-07-30 2018-06-30 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 0 -2,000 -100.00 0 -100.00
2018-04-27 2018-03-31 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 2,000 0 0.00 238 -6.30 0.2133
2018-02-05 2017-12-31 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 2,000 0 0.00 254 8.09 0.2188
2017-11-01 2017-09-30 13F ALNYLAM PHARMACEUTICALS INC COM Common Stock 02043Q107 2,000 2,000 235 0.2135
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.